147 related articles for article (PubMed ID: 22442494)
1. Secreted virulence factors and immune evasion in visceral leishmaniasis.
Lambertz U; Silverman JM; Nandan D; McMaster WR; Clos J; Foster LJ; Reiner NE
J Leukoc Biol; 2012 Jun; 91(6):887-99. PubMed ID: 22442494
[TBL] [Abstract][Full Text] [Related]
2. An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages.
Silverman JM; Clos J; de'Oliveira CC; Shirvani O; Fang Y; Wang C; Foster LJ; Reiner NE
J Cell Sci; 2010 Mar; 123(Pt 6):842-52. PubMed ID: 20159964
[TBL] [Abstract][Full Text] [Related]
3. Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1.
Nandan D; Reiner NE
Clin Immunol; 2005 Mar; 114(3):266-77. PubMed ID: 15721837
[TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani activates SREBP2 to modulate macrophage membrane cholesterol and mitochondrial oxidants for establishment of infection.
Mukherjee M; Basu Ball W; Das PK
Int J Biochem Cell Biol; 2014 Oct; 55():196-208. PubMed ID: 25218172
[TBL] [Abstract][Full Text] [Related]
5. Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production.
Forget G; Gregory DJ; Whitcombe LA; Olivier M
Infect Immun; 2006 Nov; 74(11):6272-9. PubMed ID: 17057094
[TBL] [Abstract][Full Text] [Related]
6. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
Reiner NE
J Immunol; 1987 Mar; 138(6):1919-25. PubMed ID: 3493291
[TBL] [Abstract][Full Text] [Related]
7. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
8. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
9. Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein.
McCall LI; Matlashewski G
Mol Microbiol; 2010 Jul; 77(2):518-30. PubMed ID: 20497497
[TBL] [Abstract][Full Text] [Related]
10. Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells.
Silverman JM; Clos J; Horakova E; Wang AY; Wiesgigl M; Kelly I; Lynn MA; McMaster WR; Foster LJ; Levings MK; Reiner NE
J Immunol; 2010 Nov; 185(9):5011-22. PubMed ID: 20881185
[TBL] [Abstract][Full Text] [Related]
11. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
13. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
14. Leishmania cell surface prohibitin: role in host-parasite interaction.
Jain R; Ghoshal A; Mandal C; Shaha C
Cell Microbiol; 2010 Apr; 12(4):432-52. PubMed ID: 19888987
[TBL] [Abstract][Full Text] [Related]
15. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages.
Basu R; Roy S; Walden P
J Infect Dis; 2007 May; 195(9):1373-80. PubMed ID: 17397010
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
Arora SK; Pal NS; Mujtaba S
Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
[TBL] [Abstract][Full Text] [Related]
17. Alteration of Leishmania donovani infection levels by selective impairment of macrophage signal transduction.
Moore KJ; Labrecque S; Matlashewski G
J Immunol; 1993 May; 150(10):4457-65. PubMed ID: 8482844
[TBL] [Abstract][Full Text] [Related]
18. Subversion of host cell signalling by the protozoan parasite Leishmania.
Gregory DJ; Olivier M
Parasitology; 2005; 130 Suppl():S27-35. PubMed ID: 16281989
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
